Biology of Prostate Cancer

前列腺癌生物学

• 批准号: 9282702
• 负责人: KAREN E KNUDSEN
• 金额: $ 2.71万
• 依托单位: THOMAS JEFFERSON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9282702
• 关键词: Biology; Breast; Cancer Biology; Cancer Center; Cessation of life; Clinical; Clinical Trials; Detection; Development; Diagnosis; Disease; Disease Management; Endocrine; Genitourinary system; Goals; Grant; Hormones; Institution; Instruction; Malignant - descriptor; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of prostate; Neoplasm Metastasis; Peer Review; Philadelphia; Physicians; Play; Prevention strategy; Prostate; Publications; Recruitment Activity; Research Personnel; Role; Scientist; Translating; Translational Research; United States; Universities; Urogenital Cancer; advanced disease; anticancer research; cancer prevention; cost; effective therapy; improved; male; novel; oncology; predictive marker; programs; treatment strategy; tumor progression; working group

PROJECT SUMMARY (See instructions): The Blology of Prostate Cancer (BPC) Program at the Kimmel Cancer Center (KCC) is a new program that emanated from the former Endocrine Mechanisms and Hormone Action in Cancer (EMHAC) Program, and represents the section of the EHMAC that focused on prostate cancer. From 2007 to 2011, EMHAC increased the number of highly productive investigators studying either breast/gynecological malignancies or prostate/genitourinary cancers, allow^ing the strategic creation of the BPC program in 2011. During this same interval, the Greater Philadelphia Prostate Cancer Working Group was founded by new recruit Dr. Karen Knudsen, and served as a basis for development of the BPC and the associated consortium. The BPC program consists of 18 investigators from 10 departments and 3 institutions. The Program currently brings in $2.3 million/year in total costs from NCI grants and $4.1 million/year total peer-reviewed costs. Since 2007, the program produced 343 publications of which, 10% of publications were intra-programmatic, 43% were inter-programmatic, and 5% were both inter- and intra-programmatic. Dr. Karen E. Knudsen (Leader) is an accomplished investigator with expertise in basic and translational prostate cancer research. Dr. Gomella, the Co-Leader (TJU) of BPC, provides clinical expertise in genitourinary malignancies. Dr. Fatatis the Co-leader (Drexel University) of BPC is an accomplished physician scientist with expertise in cancer metastasis at the basic and clinical level. He will play a pivotal role integrating Drexel University and TJU cancer researchers in the BPC Program. The goals of the BPC program are to leverage the significant translational and clinical expertise in genitourinary oncology (most especially with regard to prostate cancer) with the intent to: delineate the mechanisms that underpin prostate cancer development and progression, identify novel means to treat advanced disease, and improve disease management by translating these findings into clinical trials. Studies within the program are directed at developing new strategies for effective detection,diagnosis,and cure. Specific aims of this program are to;1. Develop new strategies for prevention, detection, and subtyping of early stage prostate malignancies; 2. Define the impact of hormone action in malignant disease development and prostate cancer progression; 3. Develop novel treatment strategies for prostate malignancies;4. Develop predictive markers for rational therapy delivery.

项目总结（见说明）： Kimmel癌症中心（KCC）的前列腺癌生物学（BPC）计划是一个新的计划，起源于前内分泌机制和激素在癌症中的作用（EMHAC）计划，代表了EHMAC专注于前列腺癌的部分。从2007年到2011年，EMHAC增加了研究乳腺/妇科恶性肿瘤或前列腺/泌尿生殖系统癌症的高产研究人员的数量，从而在2011年战略性地创建了BPC计划。在此 在同一时期，大费城前列腺癌工作组由新招募的Karen Knudsen博士成立，并作为BPC和相关联盟发展的基础。BPC计划由来自10个部门和3个机构的18名调查员组成。该计划目前每年从NCI赠款中获得230万美元的总费用，每年同行审查的总费用为410万美元。 自2007年以来，该计划出版了343份出版物，其中10%是计划内出版物，43%是计划间出版物，5%是计划间和计划内出版物。Karen E.博士Knudsen（领导者）是一位有成就的研究者，在基础和转化前列腺癌研究方面具有专业知识。Gomella博士是BPC的联合负责人（TJU），提供泌尿生殖系统恶性肿瘤的临床专业知识。Fatatis博士是BPC的联合领导人（德雷克塞尔大学），是一位有成就的医生科学家，在基础和临床水平上具有癌症转移方面的专业知识。他将发挥关键作用，整合德雷克塞尔大学和TJU癌症研究人员在BPC计划。 BPC计划的目标是利用泌尿生殖肿瘤学（特别是前列腺癌）的重要转化和临床专业知识，旨在：描述支持前列腺癌发展和进展的机制，确定治疗晚期疾病的新方法，并通过将这些发现转化为临床试验来改善疾病管理。该计划内的研究旨在开发有效检测，诊断和治疗的新策略。 该计划的具体目标是：1。发展预防、检测和早期前列腺恶性肿瘤分型的新策略; 2.明确激素作用对恶性疾病发展和前列腺癌进展的影响; 3.开发前列腺恶性肿瘤的新治疗策略;4.制定合理治疗的预测指标。